How GLP-1 Medicines Are Changing Pharmaceutical Manufacturing Priorities

When Demand Outruns the Factory

For most of the industry's history, commercial success has been decided in the laboratory and the clinic. Manufacturing was treated as a dependable back office, a function expected to scale quietly once a product was approved. GLP-1 medicines have overturned that assumption.

Originally developed for type 2 diabetes, this class of peptide therapies has expanded into chronic weight management and a growing list of cardiometabolic indications. Patient demand has grown faster than almost anyone forecast, and for an extended period the limiting factor on revenue was not clinical evidence, pricing or market access. It was the physical ability to produce, fill and ship enough product.

That experience has turned manufacturing into a boardroom topic. For US pharmaceutical leaders, the GLP-1 story is no longer only about one therapeutic class. It is a preview of how capacity, supply chain control and production technology will shape competitive advantage across the industry. The sections that follow examine how the shortage era unfolded, why peptides are so demanding to produce, what recent capacity investments reveal and which decisions now belong on the executive agenda.

The Shortage Era: A Wake-Up Call Written in Empty Pharmacy Shelves

The clearest signal of the manufacturing challenge came from the US Food and Drug Administration's drug shortage list. Both of the leading GLP-1 molecules spent an extended period on it as supply struggled to keep pace with prescriptions.

The FDA revised the shortage status for all tirzepatide presentations to resolved in October 2024, a decision the agency confirmed through a declaratory order on 19 December 2024. Semaglutide followed when the FDA determined on 21 February 2025 that its shortage had been resolved. The agency then set wind-down periods for compounded copies, giving state-licensed pharmacies until 22 April 2025 and outsourcing facilities until 22 May 2025.

The commercial lesson is stark. While shortages persisted, patients faced interruptions, prescribers lost confidence and compounded alternatives filled the gap. Supply constraints did not merely delay revenue; they opened the door to competition and regulatory complexity that manufacturers could not fully control. For executives, the shortage era demonstrated that capacity is a strategic asset that protects market position, not simply an operating cost.

Why Peptides Rewrite the Production Playbook

GLP-1 medicines sit in an unusual space between small molecules and biologics, and that position creates distinctive manufacturing demands.

The active ingredients are peptides, typically produced through chemical synthesis that builds the molecule step by step. These processes are complex, solvent-intensive and difficult to scale quickly. Purification adds further time and cost, and specialised capacity for large-volume peptide production has historically been limited.

The bottleneck does not end with the active ingredient. Most GLP-1 therapies are delivered as injectables in prefilled pens, which means aseptic fill-finish operations and device assembly become critical constraints. A company can have enough active ingredient and still be unable to supply patients if it lacks sterile filling lines or pen components. Every link in the chain, from raw materials to device assembly, must scale together, and the slowest link determines total output.

This has pushed leadership teams to think about manufacturing as an integrated system. The priority is no longer optimising individual plants but synchronising the entire network so that drug substance, fill-finish and devices expand in step.

Case Study One: Buying Capacity Instead of Building It

One of the most striking manufacturing moves of recent years shows how far companies will go to secure fill-finish capacity. In early 2024, a holding entity agreed to acquire a major contract development and manufacturing organisation for USD 16.5 billion. As part of the arrangement, three of the acquired sites were to be sold to an affiliated GLP-1 manufacturer for USD 11 billion upfront.

The three facilities, located in Bloomington, Indiana; Brussels, Belgium; and Anagni, Italy, employed more than 3,000 people combined. The buyer stated clearly that the purpose was to address supply constraints on its semaglutide products, where demand had outpaced its ability to produce.

The strategic logic deserves attention. Building new sterile manufacturing capacity from the ground up can take years, including design, construction, validation and regulatory approval. Acquiring operational, approved facilities compresses that timeline. The trade-off is cost: paying a substantial premium for speed. For C-suite leaders, the case illustrates a new calculation in which time-to-capacity can justify valuations that would once have seemed difficult to defend.

Case Study Two: Betting Billions on the Active Ingredient

A second example shows the same urgency applied further upstream. In May 2024, another leading GLP-1 manufacturer announced an additional USD 5.3 billion investment in its manufacturing site in Lebanon, Indiana, dedicated to producing the active pharmaceutical ingredient tirzepatide.

The new commitment came only weeks after an initial plan of USD 3.7 billion for the same location, bringing the total investment at that single site to USD 9 billion. The speed of the escalation is itself instructive: forecasts were revised upward faster than construction could begin.

Concentrating API production domestically also aligns with a broader US policy emphasis on supply chain resilience. For executives, the case demonstrates that control of the active ingredient, rather than reliance on external suppliers, has become a source of competitive security in high-demand therapeutic classes.

The Oral Shift: A New Equation for Active Ingredient Supply

Just as injectable supply began to stabilise, a new variable arrived. On 22 December 2025, the FDA approved the first oral GLP-1 receptor agonist for chronic weight management, a once-daily semaglutide tablet at a 25 mg dose.

Oral formulations promise to broaden access by removing the need for injections, cold-chain-dependent pens and sterile fill-finish. Yet they also reshape manufacturing priorities in a less obvious way. A patient on the standard 2.4 mg weekly injectable maintenance dose receives far less active ingredient than a patient taking a 25 mg tablet every day, which adds up to 175 mg per week, more than 70 times as much.

The implication for leadership is significant. Oral products shift the bottleneck away from sterile filling and device assembly and back towards large-scale peptide synthesis. Companies that planned capacity around injectables must now model a future in which drug substance volume, not fill-finish, becomes the dominant constraint.

Portfolio mix will matter too. Many organisations will need to supply injectables and tablets side by side for years, serving patients with different preferences and clinical needs. That requires flexible facilities, careful allocation of scarce peptide capacity between formats and pricing strategies that reflect the very different production economics of each.

The Green Imperative: Scaling Without Scaling the Footprint

Rapid expansion brings a sustainability challenge that boards cannot ignore. Conventional peptide synthesis relies on large volumes of solvents and reagents, and much of that material becomes waste once the final product is purified. When production grows from modest volumes to the scale demanded by chronic disease populations numbering in the millions, the environmental footprint grows with it.

Investors, payers and regulators are paying closer attention to how medicines are made, not only what they deliver. Companies are therefore exploring greener chemistry, solvent recovery, hybrid production approaches and continuous processing that can raise yields while cutting waste. These technologies require upfront capital and process redevelopment, but they also lower long-term operating costs and reduce exposure to raw material constraints.

For leadership teams, sustainability in GLP-1 manufacturing is not a reputational extra. It is directly linked to cost of goods, supply security and the ability to scale responsibly over a product lifecycle that may extend across decades of chronic treatment.

People, Quality and Compliance: The Hidden Constraints

Concrete, steel and equipment can be purchased. Experienced people are harder to find. Sterile manufacturing, peptide chemistry and quality assurance all demand specialised skills, and rapid expansion across the industry has intensified competition for the same pool of talent.

Quality systems face similar strain. Every new line, site or contract partner must meet current good manufacturing practice standards, and every change must be documented and, where required, approved by regulators. A capacity expansion that outpaces quality oversight risks inspection findings, recalls or delays that undo the very supply gains it was meant to deliver.

Forward-looking companies are responding by investing in workforce development, digital quality tools and closer partnerships with technical training programmes. They are also building regulatory engagement into expansion timelines from the start, treating compliance readiness as part of the capacity plan rather than a final checkpoint before launch.

The Boardroom Agenda: Five Priorities for US Pharma Leaders

The GLP-1 experience offers lessons that extend well beyond a single class of medicines. Five priorities stand out for leadership teams.

• Plan capacity ahead of approval. Commit manufacturing investment earlier in development, accepting some risk in exchange for readiness at launch.
• Secure the full chain. Treat active ingredient, sterile fill-finish, devices and packaging as a single integrated system with shared capacity planning.
• Weigh build versus buy rigorously. Evaluate acquisitions of approved capacity against greenfield construction with time-to-supply as a central metric.
• Invest in process innovation. Prioritise greener, higher-yield peptide synthesis and continuous manufacturing to lower cost and environmental impact at scale.
• Model formulation scenarios. Stress-test supply strategies for both injectable and oral products, since each places very different demands on the network.

Conclusion: Manufacturing Is the New Frontline of Competition

GLP-1 medicines have shown that in a high-demand market, the ability to produce can matter as much as the ability to discover. Shortages revealed how quickly supply gaps erode patient trust and invite competition. Multibillion-dollar acquisitions and plant investments revealed how seriously the industry now treats capacity. The arrival of oral formulations has shown that the manufacturing challenge will keep evolving.

For US pharmaceutical executives, the message is clear. Manufacturing strategy can no longer follow commercial strategy; it must be built alongside it. Organisations that integrate capacity planning into portfolio decisions, invest in flexible and efficient production technologies and secure control over critical supply links will be best positioned for the next wave of high-demand medicines. The companies that lead the coming decade will be those that treat the factory floor as a strategic asset, not an afterthought.